research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
Search
for
Sort by
Research
240-270 / 1000+ results
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
research ACE1 rs1799752 polymorphism is not associated with long-COVID symptomatology in previously hospitalized COVID-19 survivors
The ACE1 gene variant doesn't affect long-COVID symptoms.
research FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial
The trial aims to test if spironolactone is an effective acne treatment for women without the side effects of current treatments.
research COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d’Andrologie de langue Française SALF)
Wait 3 months after COVID-19 before trying assisted reproduction and further research is needed on COVID-19's effects on male hormones and fertility.
research Doxazosin and finasteride alone or in combination: the PREDICT study
Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
research Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster
Hair loss may link to weaker COVID-19 immunity, suggesting possible need for extra vaccine boost.
research A new combination of molecules for the treatment of androgenetic alopecia and telogen effluvium: a double-blind randomized, monocentric, placebo-controlled study
The combination of arginine and zinc reduces hair loss and increases hair growth effectively.
research Lilly arthritis drug approved for alopecia
The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
research Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination
COVID-19 may trigger alopecia areata, but more research is needed.
research New potential chemotherapy for ovarian cancer — Combined therapy with WP 631 and epothilone B
The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
research Role of ACE2 polymorphism in COVID-19: impact of age
Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.
research SMART Pharmacists Serving the New Needs of the Post-COVID Patients, Leaving No-One Behind
Pharmacist-led care significantly improved post-COVID symptoms.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research COVID‐19, androgens, and androgenic alopecia
COVID-19 may worsen with androgens; anti-androgen drugs could help.
research Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial
Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
research Alpha Xtra Boost Review (USA): Is Alpha Xtra Boost Male Enhancement Supplement Legit or Scam?
research Lymphoma Specialists Lament the Discontinuation of Underprescribed Bexxar
Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
research Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
research Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19
Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
research Increased anxiety from fear of Omicron in China as compared to North America and Western Europe: A cross-sectional Kendall’s tau-b analysis using the generalized anxiety disorder 7-item questionnaire
Anxiety about Omicron was higher in China than in North America and Western Europe.
research SARS‐COV2 Vaccination and Hidradenitis Suppurativa: Role of Vaccination in Disease Activity
COVID-19 vaccination is generally safe for people with Hidradenitis Suppurativa.
research The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis
Canakinumab's effect on COVID-19 outcomes is unclear.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Dr Reddy's Laboratories has announced the launch of its finasteride and simvastatin tablets,
research Dermatological Adverse Effects of Covid-19 Vaccine among Healthcare Workers: Findings from a Tertiary Care Hospital in Northern India
Few healthcare workers had skin reactions after Covid-19 vaccination.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.